Last reviewed · How we verify
ISIS-FGFR4RX
Antisense oligonucleotide targeting fibroblast growth factor receptor 4
Antisense oligonucleotide targeting fibroblast growth factor receptor 4 Used for Solid tumors.
At a glance
| Generic name | ISIS-FGFR4RX |
|---|---|
| Also known as | ISIS 463588 |
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Drug class | antisense oligonucleotide |
| Target | FGFR4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ISIS-FGFR4RX is an antisense oligonucleotide that specifically targets fibroblast growth factor receptor 4 (FGFR4) to reduce its expression and activity.
Approved indications
- Solid tumors
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |